<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688829</url>
  </required_header>
  <id_info>
    <org_study_id>Firehawk_FIM</org_study_id>
    <nct_id>NCT02688829</nct_id>
  </id_info>
  <brief_title>The First-In-Man Pilot Study of Firehawk</brief_title>
  <official_title>The Initial Small-Scale Clinical Study of Rapamycin-Eluting Coronary Stent System of Microport (Firehawk)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small-scale pilot clinical study of the Rapamycin-Eluting Coronary Stent System of
      Microport for the first time to assess the preliminary safety and feasibility used in the
      human body. And provide evidence for subsequent large-scale, multi-center, randomized
      controlled clinical trials, then provide the basis for the formal application of the product
      in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Participants With MACE (Major Acute Cardiovascular Events)</measure>
    <time_frame>1 month after stent implantation</time_frame>
    <description>Count of Participants who have major acute cardiovascular events (MACE) in 1 month follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent Late Lumen Loss</measure>
    <time_frame>4 months after stent implantation</time_frame>
    <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 4 months follow-up in-stent minimal lumen diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With MACE (Major Acute Cardiovascular Events)</measure>
    <time_frame>4 month after stent implantation</time_frame>
    <description>Count of Participants who have major acute cardiovascular events (MACE) in 4 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of In-stent Diameter Stenosis</measure>
    <time_frame>4 months after stent implantation</time_frame>
    <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Late Lumen Loss</measure>
    <time_frame>13 month after stent implantation</time_frame>
    <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 13 months follow-up in-stent minimal lumen diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With MACE (Major Acute Cardiovascular Events)</measure>
    <time_frame>13 month after stent implantation</time_frame>
    <description>Count of Participants who have major acute cardiovascular events (MACE) in 13 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of In-stent Diameter Stenosis</measure>
    <time_frame>13 month after stent implantation</time_frame>
    <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin target-eluting Coronary Stent System</intervention_name>
    <description>Implantation of the rapamycin-eluting coronary stent system</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Firehawk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75 years of age, males or non-pregnant females;

          2. With silent ischemia evidence, patients with stable or unstable angina, or in patients
             with old myocardial infarction;

          3. Total number of target lesion is 1;

          4. Target lesion length ≤ 30mm (Visual); target lesion diameter between 2.25mm to 4.0mm;

          5. Visual assessment of target lesion diameter stenosis ≥ 70%,TIMI blood flow≥1;

          6. Each target lesion may be covered by a single stent;

          7. Patients with indications for coronary artery bypass graft surgery;

          8. To understand the purpose of testing, voluntary and informed consent, patients
             undergoing invasive imaging follow-up.

        Exclusion Criteria:

          1. Within 1 month of any acute myocardial infarction;

          2. Chronic total occlusion (TIMI grade 0 flow before surgery), left main coronary artery
             disease, mouth lesions, multiple-vessel lesions, branch diameter ≥ 2.5mm bifurcation
             lesions and vascular lesions of the bridge;

          3. Severe calcified lesions that cannot be successfully expanded and distorting lesions
             not suitable for stent delivery;

          4. In-stent Restenosis lesions;

          5. Intracoronary implantation of any branding stents within 1 year;

          6. Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection
             fraction or &lt;40% (ultrasound or left ventricular angiography);

          7. Preoperative renal function serum creatinine &gt;2.0mg/DL;

          8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage
             and half year history of ischemic stroke, antiplatelet agents and would not allow an
             anticoagulant therapy contraindications patients undergoing antithrombotic therapy;

          9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin
             allergies;

         10. The patient's life expectancy is less than 12 months;

         11. Top participated in other drug or medical device and does not meet the primary study
             endpoint in clinical trials time frame;

         12. Researchers determine patient compliance is poor, unable to complete the study in
             accordance with the requirements;

         13. Heart transplantation patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <results_first_submitted>September 4, 2019</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2019</results_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sirolimus eluting stents</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>First in man</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
        <description>Count of Participants who have major acute cardiovascular events (MACE) in 1 month follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
        <time_frame>1 month after stent implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
          <description>Count of Participants who have major acute cardiovascular events (MACE) in 1 month follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Late Lumen Loss</title>
        <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 4 months follow-up in-stent minimal lumen diameter.</description>
        <time_frame>4 months after stent implantation</time_frame>
        <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Lumen Loss</title>
          <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 4 months follow-up in-stent minimal lumen diameter.</description>
          <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
        <description>Count of Participants who have major acute cardiovascular events (MACE) in 4 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
        <time_frame>4 month after stent implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
          <description>Count of Participants who have major acute cardiovascular events (MACE) in 4 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of In-stent Diameter Stenosis</title>
        <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
        <time_frame>4 months after stent implantation</time_frame>
        <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of In-stent Diameter Stenosis</title>
          <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
          <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
          <units>percentage of lumen diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Late Lumen Loss</title>
        <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 13 months follow-up in-stent minimal lumen diameter.</description>
        <time_frame>13 month after stent implantation</time_frame>
        <population>Angiographic follow-up at 13months was obtained in 19 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Lumen Loss</title>
          <description>In-stent late lumen loss (In-stent LLL) is defined as the difference between the post-procedure and 13 months follow-up in-stent minimal lumen diameter.</description>
          <population>Angiographic follow-up at 13months was obtained in 19 patients.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
        <description>Count of Participants who have major acute cardiovascular events (MACE) in 13 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
        <time_frame>13 month after stent implantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With MACE (Major Acute Cardiovascular Events)</title>
          <description>Count of Participants who have major acute cardiovascular events (MACE) in 13 months follow-up, MACE defined as the composite of cardiac death, myocardial infarction(Q and non-Q) and ischemia driven target lesion revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of In-stent Diameter Stenosis</title>
        <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
        <time_frame>13 month after stent implantation</time_frame>
        <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of In-stent Diameter Stenosis</title>
          <description>Percentage of in-stent diameter stenosis is calculated by the following fomula: (RVD‐MLD)/RVD * 100%.
RVD: Reference vessel diameter, represents the averaged diameter of the coronary assumed without atherosclerotic disease.
MLD: Minimal luminal diameter, represents the smallest lumen diameter in the segment of interest.</description>
          <population>Angiographic follow-up at 4 months was obtained in 19 patients.</population>
          <units>percentage of lumen diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
Rapamycin target-eluting Coronary Stent System: Implantation of the rapamycin-eluting coronary stent system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TVR</sub_title>
                <description>Target vessel revascularization, defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <description>Hemorrhagic stroke is defined as a sudden onset of focal neurological deflicits due to cebral vascular bleeding that lasts more than 24 hours.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Zhang Haotian</name_or_title>
      <organization>Microport Medical, Shanghai, China</organization>
      <phone>8621-38954600 ext 8552</phone>
      <email>zhanght@microport.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

